According to the company, MyPRS Plus helps gain further insights of individual’s genetic characteristics and also determines the molecular sub-group to which each patient belongs.
The relapse and survival available for Myeloma patients can be predicted by classifying the genetic characteristics and molecular sub-groups.
Myeloma Health Research EVP John Shaugnessy said this classification would enable in better understanding of the genetic abnormalities of the patients by the physicians.